Matthew Pommer

Morgan Stanley on Wednesday issued a report on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) after the company reported guidance that was below estimates. Regeneron is currently rated as Overweight with a price target of $499.00. Analysts Matthew Harrison, Matthew Pommer and Amy Le wrote, "the...

In a report published Thursday, Oppenheimer analyst Matthew Pommer reiterated an Outperform rating on Fluidigm (NASDAQ: FLDM), and raised the price target from $28.00 to $35.00. In the report, Oppenheimer noted, “We are increasing our price target and 2013-14 projections following discussions with...

Analysts Matt Dolan and Matthew Pommer at Roth Capital Partners have released a report on the Medical Devices industry. Roth Capital Partners conducted a survey among C-level executives at small medical devices companies to gauge the expected impact of the healthcare reform. According to analysts...